Jubilant Ingrevia's Declared Q1FY 26 Results - June Quarter Profit Up by 54%

Noida, July 31, 2025 – Jubilant Ingrevia Ltd (NSE: JUBLINGREA, BSE: 543271) announced a 54% year-on-year rise in consolidated net profit for Q1FY26, driven by cost control and stable revenue. The company also highlighted strategic progress in green energy, completing its investment in O2 Renewable Energy XVIII Pvt Ltd during the quarter.

Speciality Chemicals led segment profits with ₹106.23 crore, supported by steady demand and better realisations. Nutrition & Health Solutions remained stable, while Chemical Intermediates saw muted growth. Cost containment and steady earnings per share indicate continued operating discipline across business verticals.

Jubilant Ingrevia Stock Performance as of July 31, 2025

As of 14:49 IST on July 31, Jubilant Ingrevia traded at ₹792.70, down 2.21% from the previous close of ₹810.60. The stock hit an intraday high of ₹845.55 and low of ₹784.45, with VWAP at ₹818.94 on a turnover of ₹99.95 crore.

Consolidated Financial Performance

Jubilant Ingrevia Ltd reported consolidated revenue from operations of ₹1,037.95 crore in Q1FY26, marginally down from ₹1,051.26 crore in Q4FY25 but up from ₹1,024.34 crore in Q1FY25. Total expenses remained stable at ₹949.34 crore, keeping cost pressure contained despite a slight dip in income.

Net profit rose to ₹75.10 crore from ₹48.74 crore a year ago, while also improving over ₹74.05 crore in the previous quarter. Total comprehensive income reached ₹85.17 crore. Earnings per share stood at ₹4.75, slightly higher than both Q4FY25 and Q1FY25, reflecting stable profitability and cost control.

Segment-Wise Revenue and Profit

The Speciality Chemicals segment recorded revenue of ₹536.97 crore, supported by steady demand and improved realisations. It also delivered the highest segment profit (PBIT) at ₹106.23 crore, indicating strong margin strength within the portfolio.

Nutrition & Health Solutions generated ₹178.87 crore in revenue and contributed ₹19.99 crore in profit, reflecting stable operating performance. Chemical Intermediates brought in ₹381.65 crore in revenue but posted a modest profit of ₹4.97 crore, pointing to muted margins and flat segment growth.

Strategic Developments

Jubilant Ingrevia completed its third tranche investment in O2 Renewable Energy XVIII Pvt Ltd, now classified as an associate. This supports captive green energy sourcing through a hybrid solar-wind setup. As of June 30, 2025, the company had ₹150 crore in listed commercial papers outstanding, due for redemption in July.

Management Commentary

Deepak Jain, CEO & Managing Director, commented, “Despite sequential moderation, our performance reflects resilience and margin protection amid a volatile environment. Strategic investments in green energy and innovation continue to strengthen our long-term competitiveness.”

Outlook

Cost discipline and steady margins supported earnings growth, but flat revenue and weak Chemical Intermediates performance raise concerns. The market is reacting to margin pressure and muted topline traction. Sustained gains will depend on revenue expansion and segment-level profitability recovery.

About Jubilant Ingrevia Limited

Jubilant Ingrevia Limited is a global integrated life science company offering speciality chemicals, nutritional ingredients, and custom solutions. It serves the pharmaceutical, nutrition, agrochemical, and consumer care sectors, and leads globally in Pyridine and its derivatives manufacturing.

REF:https://www.bseindia.com/xml-data/corpfiling/AttachLive/45280c02-28a8-407a-95f3-a7927f5aecc1.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations